Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VK2809 in Primary Hypercholesterolemia and NAFLD
NCT02927184Phase 2Completed
- Sponsor
- Viking Therapeutics
- Start
- Sep 2016
- Primary completion
- Mar 2019
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of VK2809 in hypercholesterolemia and non-alcoholic fatty liver disease (NAFLD) (4 arms), sponsored by Viking Therapeutics. Primary endpoint: Percent Change from Baseline in LDL-C at 12 weeks. Started Sep 2016; status: completed.
02
Drugs
VK2809
03
Conditions
hypercholesterolemianon-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02927184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02927184.